.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Farmers Insurance
Queensland Health
McKesson
Cipla
Chinese Patent Office
Novartis
Chubb
Express Scripts
McKinsey

Generated: July 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,303,661

« Back to Dashboard

Which drugs does patent 6,303,661 protect, and when does it expire?


Patent 6,303,661 protects KAZANO, JENTADUETO XR, OSENI, JUVISYNC, JANUMET, JANUMET XR, NESINA, GLYXAMBI, TRADJENTA, JENTADUETO, and JANUVIA, and is included in eleven NDAs. There have been zero Paragraph IV challenges on Kazano, Nesina, Tradjenta, Jentadueto, Juvisync, Janumet XR, , and .

This patent has fifty-one patent family members in twenty-one countries.

Summary for Patent: 6,303,661

Title: Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Abstract:Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
Inventor(s): Demuth; Hans-Ulrich (Halle, DE), Rosche; Fred (Dieskau, DE), Schmidt; Joem (Halle, DE), Pauly; Robert P. (Vancouver, CA), McIntosh; Christopher H. S. (Vancouver, CA), Pederson; Ray A. (Vancouver, CA)
Assignee: Probiodrug (Weinbergweg, DE)
Application Number:09/155,833
Patent Claim Types:
see list of patent claims
Use; Dosage form; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms Usa
KAZANO
alogliptin benzoate; metformin hydrochloride
TABLET;ORAL203414-002Jan 25, 2013RXYesYes6,303,661► Subscribe METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
Takeda Pharms Usa
KAZANO
alogliptin benzoate; metformin hydrochloride
TABLET;ORAL203414-001Jan 25, 2013RXYesNo6,303,661► Subscribe METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
Boehringer Ingelheim
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-001May 27, 2016RXYesNo6,303,661► Subscribe METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
Boehringer Ingelheim
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-002May 27, 2016RXYesYes6,303,661► Subscribe METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
Takeda Pharms Usa
OSENI
alogliptin benzoate; pioglitazone hydrochloride
TABLET;ORAL022426-004Jan 25, 2013RXYesNo6,303,661► Subscribe METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,303,661

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany196 16 486Apr 25, 1996
PCT Information
PCT FiledApril 24, 1997PCT Application Number:PCT/DE97/00820
PCT Publication Date:November 06, 1997PCT Publication Number: WO97/40832

International Patent Family for Patent: 6,303,661

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria202705► Subscribe
Australia3023397► Subscribe
Australia721477► Subscribe
Canada2252576► Subscribe
Canada2423025► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
US Department of Justice
Covington
Julphar
Boehringer Ingelheim
US Army
Cipla
Healthtrust
AstraZeneca
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot